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Abstract
Background: Depressive disorders are a common form of psychiatric illness and cause significant disability.
Regulation authorities, the medical profession and the public require high safety standards for antidepressants to
protect vulnerable psychiatric patients. Ketamine is a dissociative anaesthetic and a derivative of a hallucinogen
(phencyclidine). Its abuse is a major worldwide public health problem. Ketamine is a scheduled drug and its usage
is restricted due to its abuse liability. Recent clinical trials have reported that ketamine use led to rapid
antidepressant effects in patients suffering from treatment-resistant depression. However, various flaws in study
designs, and possible biased reporting of results, may have influenced those findings. Further analyses of ketamine
use are needed to ensure patient safety.
Discussion: The use of ketamine in research and treatment of depressive disorders is controversial. Recently,
mental health professionals raised ethical concerns about an ongoing ketamine trial in the UK. Also, a Canadian
agency reviewed the existing evidence and did not recommend prescribing ketamine to treat depressive disorders.
Findings obtained from tightly controlled research settings cannot be easily translated to clinical practice as
substance abuse is commonly comorbid with depressive disorders. An effective antidepressant should reduce
severity of depressive symptoms without liability problems. Although the US FDA has not approved the use of
ketamine to treat depressive disorders, some psychiatrists offer off-label repeat prescription of ketamine. Prescribing
ketamine for treating depressive disorders requires substantial empirical evidence. Clinicians should also consider
research findings on ketamine abuse. Depressive disorders can be chronic conditions and the current evidence
does not rule out the risk of substance abuse after repeat prescription of ketamine. Off-label ketamine use in
treating depressive disorders may breach ethical and moral standards, especially in countries seriously affected by
ketamine abuse. This article presents two real-world clinical vignettes which highlight ethical principles and
theories, including autonomy, nonmaleficience, fidelity and consequentialism, as related to off-label ketamine use.
Conclusion: We urge clinicians to minimise the risk of harming patients by considering the empirical evidence on
ketamine properties and attempting all standard antidepressant therapies before considering the off-label use of
ketamine.
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Introduction
Ketamine as an anaesthetic
Ketamine is a rapid-acting non-barbiturate dissociative
anaesthetic. It produces an anaesthetic state character-
ized by profound analgesia, with normal pharyngeal-
laryngeal reflexes. Ketamine was approved by the US
FDA as an anaesthetic for cardiac catheterization, skin
grafting, orthopaedic and extraperitoneal procedures, as
well as diagnostic procedures performed on the eye, ear,
nose and throat [1]. Ketamine has been used as a battle-
field anaesthetic because it can induce a dissociative
state, which is helpful for treating wounded soldiers by
maintaining consciousness while they are cognitively
separated from pain [2]. Ketamine does, however, have
side effects. Common side effects observed during one-
time anaesthetic use include: elevation of blood pressure
and heart rate, hallucinations, delirium, and irrational
behaviours [1]. Common side effects after ketamine infu-
sion included anxiety, confusion, dizziness, drowsiness,
intense euphoria, perceptual disturbances, hypertension,
nausea and an increase in skeletal muscle tone. More-
over, the current evidence on the safety of ketamine as
an anaesthetic applies only to medical or surgical pa-
tients for one-time usage, not to psychiatric patients
who receive multiple infusions. These adverse effects are
usually transient in nature, lasting from a few hours to
24 h. The FDA recommends administering low-dose
ketamine via the intramuscular route to reduce the oc-
currence of adverse effects [1]. Of importance, the FDA
also recommends the minimization of verbal, tactile and
visual stimulation when ketamine is administered.
Ketamine abuse
In some countries, ketamine is the most common drug
of abuse and the prevalence of health and social
problems associated with ketamine abuse are widely
acknowledged [3, 4]. In the 1970s, some individuals
started misusing ketamine. Ketamine is pharmacologically
similar to phencyclidine (PCP), a commonly abused
hallucinogen. The street name of ketamine is “K” or
“Special K.” Ketamine abuse is now common worldwide.
For example, in 2012, 1.5 % of US 12th graders reported
ketamine abuse [5]. Emergency room visits due to
ketamine abuse increased by 2000 % between 1995 and
2002 in the US [6]. In the UK, the prevalence of ketamine
abuse among recreational drug users increased from 25 to
40 % from 2002 to 2007 [7]. In Hong Kong, ketamine is
the most common drug of abuse and is consumed by
more than 80 % of drug users [3].
Drug abusers may snort ketamine powder or inject li-
quid ketamine to experience perceptual changes, dissoci-
ation and hallucinatory effects. At low doses, ketamine
can cause euphoria, sensory distortions, impairments in
set-shifting, and heightened feelings of empathy [8–10].
At high doses, ketamine can cause dissociative effects,
hallucinations, intoxication, and frightening experiences
[2]. Frequent ketamine use has been associated with am-
nesia, dependence, dissociation, lower urinary tract dys-
function, and poor impulse control [3]. The current
legal status of ketamine varies from country to country.
In the US, ketamine is a Schedule III drug under the
Controlled Substances Act, which limits control in pre-
scription due to its abuse liability [5]. US physicians can-
not authorise more than five refills of ketamine per
prescription. When ketamine tablets are distributed by
prescription, the medication bottle must state that it is a
crime to distribute ketamine to others. Individuals con-
victed of illicit possession of ketamine are subject to im-
prisonment and/or large fines. Other countries have also
rescheduled ketamine to exert tighter control due to its
abuse liability and other harmful consequences. Keta-
mine is a Class B drug in the UK and a schedule I drug
in Hong Kong. In Malaysia and Singapore, anyone
caught with ketamine faces imprisonment or strokes of
the cane [11]. Repeated offenders may face the death
penalty in Malaysia.
Major depressive disorder and existing treatment
Major depressive disorder is highly prevalent and causes
significant disability worldwide [12]. Current evidence
indicates that 70–90 % of depressed patients respond to
initial antidepressant treatment [13]. For 70 % of the pa-
tients with treatment resistant depression, combining
antidepressants, augmentation with mood stabilisers, in-
tegrating antidepressant drugs with psychosocial therap-
ies (such as cognitive behavioural therapy), and offering
electroconvulsive therapy (ECT), have been show to lead
to recovery [14].
Discussion
Clinical trials evaluating ketamine as an antidepressant
Several clinical trials, using slow intravenous (IV) infu-
sion of ketamine at sub-anaesthetic doses, explored its
effect as a rapid antidepressant. Response rates have
ranged from 29 % [15] to 79 % [16]. Rapid antidepres-
sant states from ketamine were found to be unsustain-
able, with relapse rates as high as 73 % at one month
post-treatment [17]. In addition, most of these studies
had inadequate statistical power due to small sample
sizes. Therefore, Wan et al. [18] combined results of 97
patients who received short-term IV ketamine (an aver-
age of 2.1 infusions per patient, with a mean follow-up
period of 2.9 years after the last infusion), and concluded
that ketamine treatments were safe and well tolerated.
Most published clinical trials of ketamine as an anti-
depressant included only depressed patients without a
history of substance abuse, which is uncommon in the
clinical population. Therefore, those findings may not be
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generalisable as there is insufficient data to demonstrate
safe prolonged use of ketamine [18]. Several researchers
and their affiliated medical schools declared that they
own patents for using ketamine to treat depression and
would therefore benefit financially if the FDA approves
its use in treating depressive disorders [19–21]. There-
fore, some researchers may have been motivated by fi-
nancial interests.
Off-label repeat prescription of ketamine
There are clinicians offering off-label usage of ketamine
as a treatment option for treatment resistant depression
[22]. Off-label usage refers to the prescription of a medi-
cation to treat a condition which has not been approved
by the FDA, and there is insufficient medical evidence to
support such application [23]. Due to the low remission
rate and short half-life of ketamine, researchers have ad-
vocated multiple ketamine infusions to maintain its anti-
depressant effect [15, 24]. In the US, some clinics are
charging hundreds of dollars for off-label ketamine infu-
sions that have to be administered repeatedly [22]. Ras-
mussen [25] stressed that the enthusiasm of advocating
repeated infusions of ketamine to maintain its anti-
depressant effect must be tempered by its addiction li-
ability and tolerance effects. Off-label repeat prescription
of ketamine may cause potential harm to depressed pa-
tients as depression and addiction are commonly comor-
bid [26]. More concern should be given to the fact that
addictive substances can be poor choices for treating
vulnerable populations.
Criticisms of an ongoing ketamine trial
Recently, a controversial longitudinal trial, funded by the
National Institute for Health Research (UK), which com-
bines ECT and ketamine treatment, was approved, with
recruitment currently underway [27]. The researchers
hypothesise that ketamine could reduce the cognitive
impairments associated with ECT [28]. However, fre-
quent use of ketamine also leads to cognitive impair-
ments in working memory and executive function, and
there is no previous evidence that ketamine enhances
cognitive function [29]. The administration of ketamine
with ECT is not novel. In 1972, Coppel and Dundee [30]
expressed concern that combining ketamine and ECT
led to long recovery periods, unpleasant dreams and
delirium, which did not occur with conventional anaes-
thesia. More recently, nine British mental health profes-
sionals wrote an open letter to the investigators of the
ECT-ketamine trial to express their ethical concerns
[31]. For example, they believed the participant informa-
tion sheet contained misleading information. The study
investigators claimed that “ketamine is believed to work
together with ECT to improve mood” which the mental
health professionals found may be misleading to patients
suffering from chronic depression. The open letter urged
the investigators to add a qualifier stating that such anti-
depressant effects are “short-term” or “temporary.” We
believe that it is important to inform research partici-
pants that two-thirds of patients relapsed within 1 week
after IV ketamine infusion and not all patients suffering
from major depressive disorder would respond to IV
ketamine [32]. Their requests were, however, ignored as
was a proposal to suspend the clinical trial.
Critical appraisal of current evidence
Despite preliminary data supporting the off-label usage
of ketamine as a rapid antidepressant, concerns pertain-
ing to these clinical trials have been raised. In 2014, the
Canadian agency for Drugs and Technologies in Health
reviewed previous ketamine studies and concluded there
is a lack of evidence to recommend ketamine to treat
depressive disorders [33]. That report identified flaws in
previous trials. For example, there remains a lack of dir-
ect comparisons between ketamine and other antide-
pressants, therefore it remains unknown whether
ketamine is superior, equivocal or inferior to validated
medications. Recently, several clinical trials compared
the effects of ketamine and midazolam on depression
[20] and suicidal ideation [34]. Midazolam is a benzodi-
azepine and commonly used for sedation prior to surgi-
cal procedures. Midazolam is not an antidepressant and
not recommended by any treatment guideline to treat
depressive disorders. It is not surprising that ketamine
demonstrated greater efficacy due to its acute mood ele-
vation effect. Another limitation is that most studies did
not specify previous treatment options, including psy-
chosocial interventions, and depressed participants
might have been undertreated, resulting in false resist-
ance to conventional treatment. Also, in one study, the
doses of other psychiatric medications (e.g. antidepres-
sant, mood stabilisers) were increased among ketamine
responders during the study period [15]. It remained un-
clear whether treatment responses were due to ketamine
or to an increase in doses of other psychiatric
medications.
Another research limitation is that participants were
monitored for a short period (from 230 min [35] to
21 days [36]) and these studies failed to provide reliable
estimates of the risks of ketamine if given repeatedly
over a longer period of time. Despite very limited empir-
ical evidence for using ketamine outside of research set-
tings [37], some researchers have advocated repeated
ketamine infusions to maintain its antidepressant effect
due to its short half-life [15, 24]. Some researchers have
emphasised the safety of ketamine at sub-anaesthetic
doses [18], and distinguish its effects from the high
doses used by recreational users. Others claim that keta-
mine does not cause dependence with multiple infusions
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[15], although that is not supported by current evidence.
Sub-anaesthetic doses of ketamine are associated with
psychomotor activation, which increases the addictive li-
ability of ketamine [2], according to the psychomotor
stimulant theory of drug reward [38]. Furthermore, the
rapid antidepressant effect of ketamine is not unique
and most psychedelic drugs, such as amphetamines,
demonstrate acute mood elevation effects. In the 1930s,
amphetamines were also believed to be a powerful anti-
depressant [39]. Their acute mood elevation effect is,
however, short-lived and amphetamine takers fall into
depressive states shortly after stopping use [40] (see
Fig. 1). That same phenomenon is commonly observed
after a single ketamine infusion. Patients may try to
avoid mood crashes or withdrawal by requesting more
ketamine infusions. The acute mood elevation effect is
rewarding and causes classical substance addiction. The
potential addiction associated with long-term ketamine
use is described as the “slippery ketamine slope” [41],
because patients will slip into addiction and the field of
psychiatry will slip into the unethical practice of using
inappropriate drugs to treat psychiatric conditions,
resulting in serious ethical concerns [4]. Sanacora and
Schatzberg [42] also objected to using ketamine to treat
depressive disorders and described this as a potential
“false prophecy”. Many experts argue that off-label inter-
mittent ketamine infusions may cause harm and addic-
tion, which does not adhere to the principle of non-
maleficence. In some countries, ketamine is the most
common drug of abuse and the prevalence of health and
social problems associated with ketamine abuse is widely
acknowledged [3, 43]. The off-label repeat prescription
of ketamine may be less morally acceptable in countries
where ketamine abuse is a serious public health prob-
lem. The theory of ethical relativism explains variances
in prevalence of ketamine abuse in different countries
which will influence the perception and acceptance of
the off-label use of ketamine.
Case vignettes illustrating ethical concerns related to
off-label repeat prescription of ketamine
We present two hypothetical case vignettes, based on
our clinical experiences and knowledge, to highlight pos-
sible ethical concerns surrounding off-label repeat pre-
scription of ketamine.
Case vignette 1
A 60 year-old man suffering from severe treatment re-
sistant depression presented to an outpatient psychiatrist
office requesting ECT. Previously, he did not respond to
treatment with selective serotonin reuptake inhibitors
(SSRI), serotonin noradrenaline reuptake inhibitors
(SNRI), tricyclic antidepressants (TCA), or monoamine
oxidase inhibitors (MAOI). The attending psychiatrist
decided, therefore, to try off-label repeat infusions of
ketamine, informing the patient that conventional ECT
administered to bilateral temporal regions would cause
severe memory impairment and has less efficacy com-
pared with ketamine. The psychiatrist claimed that keta-
mine is very safe, with fewer side effects than ECT. The
psychiatrist asked the patient to stop other antidepres-
sants, without explaining the unknown risks and the un-
known course of ketamine. The patient’s depression
improved shortly after ketamine infusions but relapsed
two weeks after treatment. The psychiatrist suggested
continuing ketamine infusions on a fortnightly basis and
charged him US$200 per treatment. After three years of
treatment, the patient developed urinary incontinence,
which was determined to possibly be caused by frequent
ketamine infusions.
Fig. 1 Effects after a single ketamine infusion (blue line) and effects of repeat infusions of ketamine (red line)
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Discussion of case vignette 1
Autonomy
Consideration should be given to patient treatment
choices and preferences. In this case vignette, the psych-
iatrist declined the patient’s request for ECT. This sce-
nario is common and we have encountered this situation
in our clinical practice. Similarly, in New York, there
were reports of patients suffering from severe depressive
disorders who requested ECT but were persuaded to re-
ceive ketamine infusions instead [14]. Those patients
showed minimal improvement after infusions of keta-
mine and were later administered ECT. The off-label use
of ketamine only delayed their eventual treatment. In
this case vignette, the psychiatrist failed to offer alterna-
tive treatments, such as unilateral ECT, which causes
less cognitive impairment [44]. ECT has been extensively
evaluated and recommended by the American Psychi-
atric Association (APA) as a conventional treatment in
depressive disorders [44]. In contrast, ketamine is an ex-
perimental treatment under investigation and evaluation.
The National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research estab-
lished a clear boundary between trial and conventional
treatment, and emphasised the need for informed con-
sent. The psychiatrist did not demonstrate respect for
the patient’s personal rights when he blurred the bound-
aries between conventional psychiatric treatment and
off-label repeat prescription of ketamine.
Fidelity and financial conflict of interest
In the above vignette, the patient was denied conven-
tional treatments (i.e. ECT and SSRI) and was persuaded
to consider off-label ketamine treatment. Furthermore,
there was a potential financial conflict of interest, as the
psychiatrist charged thousands of dollars for repeat off-
label infusions of ketamine, much more than the costs
of alternative treatments. The psychiatrist did not exer-
cise fidelity which is based upon the virtue of caring. It
is also possible that the doctor prescribed repeated keta-
mine for personal financial gain.
Informed consent and nonmaleficience
In the vignette, the psychiatrist did not inform the pa-
tient of the empirical evidence of the possibility of side
effects, such as urinary incontinence associated with
long term use of ketamine. Instead, he presented one-
sided information about ketamine and ECT. Previous
studies reported dissociative and psychotomimetic ef-
fects after ketamine infusions, explained above [35].
Such biased information could have a detrimental effect
on depressed patients. There is also evidence that de-
pression lowers a person’s capabilities and perceived
self-efficacy [45]. As a result, depressed patients can be
vulnerable to suggestion, especially when they are
desperate for cure. In this case vignette, the psychiatrist
did not appear to adhere to the principles of informed
consent and non-maleficence.
Legal implications
As the vignette psychiatrist did not fulfill his fiduciary
duty, the patient could take legal action for the resulting
urinary incontinence. It may lead to class action suits if
more patients suffer from urinary incontinence due to
frequent ketamine infusions. Fiduciary duty is a legal ob-
ligation of doctors to act in the best interests of their pa-
tients. The patient placed total trust and confidence in
the psychiatrist to manage his depressive disorder and
protect him from harm. This case could be considered
medical negligence as it fulfils all three components of
Bolam’s test. The psychiatrist had a duty of professional
care to the patient, but as a consequence of a breach of
that duty, the patient suffered harm.
Case vignette 2
A 30-year-old woman with treatment resistant depres-
sion and a history of ketamine abuse presented to a psy-
chiatric clinic for the first time after discharge from a
hospital for suicidal ideation. She reported that she had
been on several different antidepressants that had failed,
including SSRI, TCA, and MAOI, but she did not report
her past history of ketamine and hallucinogen abuse.
The patient requested ketamine as she heard from the
media that ketamine is a safe and rapid antidepressant
which could reduce suicidal thoughts. The psychiatrist
agreed to prescribe ketamine to treat her depression and
suicidal ideation. He did not obtain collateral informa-
tion from her previous health providers. Subsequently,
the patient came to the clinic frequently and asked for
ketamine refills. The psychiatrist agreed to issue six re-
fills of ketamine in one prescription. Six months later,
the patient was arrested by police as her urine sample
was positive for ketamine and she was involved in inter-
national smuggling of ketamine. She could not recall
whether the ketamine was prescribed by her psychiatrist
or purchased abroad. She thought that ketamine was a
safe antidepressant and had been taking ketamine on a
daily basis to avoid mood crashes. She also distributed
ketamine to friends. She is facing criminal charges of
conspiracy to distribute ketamine, which carries a pen-
alty of 5 years in prison.
Discussion of case vignette 2
Capacity to give consent
For case 2, the debate is whether the patient had the
capacity to consent to off-label ketamine treatment as
she had a history of substance abuse, including ketamine
abuse. Some ethicists argue that individuals can have
reduced ability to resist desires for a drug of choice,
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limiting their capacity to give consent [4]. Abusers of
ketamine and other substances are therefore likely to dif-
fer from patients without a history of substance abuse.
The harm they may suffer could be considerable if their
consent is accepted as valid without assessing past his-
tory of substance abuse.
Non-maleficence
The psychiatrist of this vignette did not obtain collateral
information from previous health providers. The patient
continued her addiction to ketamine with the assistance
of the psychiatrist. She developed withdrawal symptoms
(i.e. mood crashes) when she ran out of ketamine. As a
result, she asked for frequent ketamine refills which
caused additional harm (i.e. addiction and legal conse-
quences). The psychiatrist was negligent in not inquiring
on the patient’s history of substance abuse and, there-
fore, did not adhere to the principle of non-maleficence.
Paying special attention to past substance abuse and
forensic history is an integral part of psychiatric assess-
ment. Most of the clinical trials studying the efficacy of
ketamine in treating major depressive disorder excluded
participants with histories of substance abuse, and
claimed that ketamine did not cause dependence with
multiple infusions after a short period of observations
[15]. Can the possibility of addiction be completely ruled
out if ketamine is prescribed repeatedly over a prolonged
period? We believe that it cannot. To see how addiction
could develop, consider the properties of ketamine.
Ketamine has high first past metabolism [46] and a short
half-life (3 h) [47]. Ketamine does not maintain acute
mood elevations, therefore, patients can crash into
depressive states shortly after stopping use [39]. Users
try to avoid crashes by taking more of the substance.
The acute mood elevation effect is rewarding and can
lead to drug addiction. As a result, off-label repeat pre-
scription of ketamine is not likely to be safe and may
cause substantial harm.
The consequentialist ethical theory
An additional argument is based on the consequentialist
ethical theory, which considers an act as ethical or un-
ethical depending on the consequences of the act. Based
on consequentialism, the off-label repeat prescription of
ketamine would be unethical for the above patient be-
cause it continued her addiction and led to her arrest. In
this case, the patient was misled by media reports which
described ketamine as a safe and rapid antidepressant.
The British Medical Journal published an article in 2015
which stated the media should not just report artificial
mood elevation effects of ketamine but also report the
risk of abuse, which is a concern for psychiatric patients
[48]. Some academic institutions, however, have issued
inflated claims of their own research results on open-
label ketamine trials in order to attract media coverage
[49]. Press releases on ketamine frequently contain sen-
sational and unsubstantiated titles such as “Ketamine:
The future of depression treatment” [50] or “Rave drug
holds promise for treating depression” [51] without
highlighting its potential for abuse, and the liability and
complications of long-term use. Media biases may not
be apparent to many patients, making it imperative that
doctors fully inform them of all treatment effects and
possibilities. Ketamine abusers can have a false percep-
tion that ketamine is relatively safe. Media reporting
guidelines may help improve patient safety by better
informing them of the potential side effects, long-term
effects, and other consequences of using drugs like
ketamine.
Legal implications
From a legal perspective, the psychiatrist in the vignette
violated the Controlled Substances Act by issuing more
than five refills of ketamine without consideration of the
patient’s history of substance abuse and her interactions
with other illicit drugs [5]. The psychiatrist failed to con-
sider potential legal implications of prescribing ketamine
to patients who might have been involved in trafficking
of ketamine from illegal sources.
Conclusions
Ethical principles and medical research are integral to
the delivery of safe and effective psychiatric treatment.
The off-label use of ketamine as an antidepressant re-
quires open debate and further research. We conclude
that ketamine may not be a safe antidepressant due to
the following reasons:
 No other antidepressant behaves as an
antidepressant at low doses but a drug of abuse at
high doses. In other words, there is no scientific
evidence showing a drug has two different
properties based on dose levels (i.e. a rapid
antidepressant at low doses and a drug of abuse at
high doses).
 The current data on ketamine safety is based on
small numbers of infusions and short periods of
observations. Some researchers claim that ketamine
does not cause addiction when it is used at a sub-
anaesthetic dose to treat depressive disorders. Allow-
ing such claims to remain unchallenged or to be ac-
cepted as sufficient evidence, could be considered
unethical treatment of patients.
As the possibility of ketamine abuse cannot be ruled
out by clinical trials conducted in tightly controlled re-
search environments, clinicians need to consider the em-
pirical evidence on the abuse liability of ketamine and its
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complications before considering off-label repeat pre-
scription. In our view, patients may have inadequate un-
derstanding of the potential harm (e.g. urinary
incontinence, addiction) associated with long-term keta-
mine use, especially as a maintenance treatment for de-
pressive disorders. Clinicians must inform their patients
of both the positive and negative aspects of ketamine.
Assessment of history of substance abuse should also be
compulsory before any off-label prescription of ketamine
is made. Patients with histories of substance abuse
should probably not receive ketamine to minimise risks
to those in care. We believe clinicians need to be more
aware of the legal status of ketamine and the impact of
ethical relativism which could affect the acceptance of
ketamine in society, especially in countries where keta-
mine abuse poses a serious threat to public health. We
therefore suggest that clinicians should minimise the risk
of inflicting harm to patients by considering the ethical
principles, the properties of ketamine, and attempting all
standard antidepressant therapies before considering off-
label repeat prescription of ketamine.
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